Target organ cross talk in cardiorenal syndrome: Animal models

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 9, 2012, Pages

  Bongartz, Lennart G ^a   Braam, Branko ^b   Gaillard, Carlo A ^c   Cramer, Maarten J ^a   Goldschmeding, Roel ^a   Verhaar, Marianne C ^a   Doevendans, Pieter A ^a   Joles, Jaap A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal models; Cardiorenal (patho )physiology; Chronic kidney disease; Heart failure

Indexed keywords

EID: 84868380092     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00392.2012     Document Type: Review

References (78)

1. Amann K, Irzyniec T, Mall G, Ritz E. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis. J Hypertens 11: 969-975, 1993.
2. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 60: 1309-1323, 2001.
3. Amann K, Neususs R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 8: 409-417, 1995.
4. Amann K, Tyralla K, Gross ML, Schwarz U, Tornig J, Haas CS, Ritz E, Mall G. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 63: 1708-1713, 2003.
5. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 42: 1079-1085, 1992.
6. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004.
7. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619, 1985.
8. Bauersachs J, Braun C, Fraccarollo D, Widder J, Ertl G, Schilling L, Kirchengast M, Rohmeiss P. Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252. J Hypertens 18: 1507-1514, 2000.
9. Baumann M, Leineweber K, Tewiele M, Wu K, Turk TR, Su S, Gossl M, Buck T, Wilde B, Heemann U, Kribben A, Witzke O. Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function. Nephrol Dial Transplant 25: 1817-1824, 2010.
10. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
11. Blum M, Yachnin T, Wollman Y, Chernihovsky T, Peer G, Grosskopf I, Kaplan E, Silverberg D, Cabili S, Iaina A. Low nitric oxide production in patients with chronic renal failure. Nephron 79: 265-268, 1998.
12. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 121: 2592-2600, 2010.
13. Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard CA, Doevendans PA, Joles JA. Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 298: R815-R823, 2010.
14. Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard CA, Steendijk P, Doevendans PA, Joles JA. The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction. Am J Physiol Heart Circ Physiol 299: H2037-H2045, 2010.
15. Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection. Hypertension 43: e14, 2004.
16. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26: 11-17, 2005.
17. Bongartz LG, Joles JA, Verhaar MC, Cramer MJ, Goldschmeding R, Tilburgs C, Gaillard CA, Doevendans PA, Braam B. Subtotal nephrectomy plus coronary ligation leads to more pronounced damage in both organs than either nephrectomy or coronary ligation. Am J Physiol Heart Circ Physiol 302: H845-H854, 2012.
18. Bro S, Bollano E, Bruel A, Olgaard K, Nielsen LB. Cardiac structure and function in a mouse model of uraemia without hypertension. Scand J Clin Lab Invest 68: 660-666, 2008.
19. Byrne CJ, McCafferty K, Kieswich J, Harwood S, Andrikopoulos P, Raftery M, Thiemermann C, Yaqoob MM. Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation 125: 1256-1265, 2012.
20. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13: 599-608, 2007.
21. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 77: 75-197, 1997.
22. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 15: 1530-1536, 2004.
23. Dikow R, Schmidt U, Kihm LP, Schaier M, Schwenger V, Gross ML, Katus HA, Zeier M, Hardt SE. Uremia aggravates left ventricular remodeling after myocardial infarction. Am J Nephrol 32: 13-22, 2010.
24. Ding SS, Qiu C, Hess P, Xi JF, Clozel JP, Clozel M. Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. Cardiovasc Res 53: 963-970, 2002.
25. Eijkelkamp WB, de Graeff PA, van Veldhuisen DJ, van Dokkum RP, Gansevoort RT, de Jong PE, de Zeeuw D, Hillege HL. Effect of first myocardial ischemic event on renal function. Am J Cardiol 100: 7-12, 2007.
26. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EG, Smaili S, Periyasamy SM, Hariri IM, Fedorova L, Liu J, Wu L, Kahaleh MB, Xie Z, Malhotra D, Fedorova OV, Kashkin VA, Bagrov AY, Shapiro JI. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49: 215-224, 2007.
27. Fujihara CK, De Nucci G, Zatz R. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 5: 1498-1507, 1995.
28. Gardiner SM, Compton AM, Kemp PA, Bennett T. Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br J Pharmacol 101: 625-631, 1990.
29. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4: 2023-2031, 1994.
30. Griffin KA, Picken MM, Churchill M, Churchill P, Bidani AK. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 11: 497-506, 2000.
31. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884-890, 1995.
32. Hatori N, Havu N, Hofman-Bang C, Clyne N, Pehrsson SK. Myocardial morphology and cardiac function in rats with renal failure. Jpn Circ J 64: 606-610, 2000.
33. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Bohm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 23: 1250-1257, 2012.
34. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210, 2000.
35. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24: 412-420, 2003.
36. Homma T, Sonoda H, Manabe K, Arai K, Mizuno M, Sada T, Ikeda M. Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome. Am J Physiol Renal Physiol 302: F750-F761, 2012.
37. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 55: 669-675, 1984.
38. Jie KE, Verhaar MC, Cramer MJ, van der Putten K, Gaillard CA, Doevendans PA, Koomans HA, Joles JA, Braam B. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291: F932-F944, 2006.
39. Joles JA, Bongartz LG, Gaillard CA, Braam B. Renal venous congestion and renal function in congestive heart failure. J Am Coll Cardiol 54: 1632-1633, 2009.
40. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002.
41. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ, Periyasamy SM, Xie Z, Malhotra D, Fedorova OV, Bagrov AY, Shapiro JI. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 294: F450-F454, 2008.
42. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47: 488-495, 2006.
43. Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, Mizel D, Zhou H, Wright EC, Kopp JB, Schnermann J, Yuen PS, Star RA. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int 78: 1136-1153, 2010.
44. Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H. Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. Am J Physiol Heart Circ Physiol 302: H1884-H1893, 2012.
45. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Kanamori H, Li L, Ogino A, Ohno T, Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J Card Fail 13: 155-162, 2007.
46. Liu S, Kompa AR, Kelly DJ, Krum H, Wang BH. Subtotal nephrectomy accelerates pathological cardiac remodelling post myocardial infarction: recapitulating the phenotype of cardiorenal syndrome? (Abstract). Circulation 124: A11507, 2011.
47. Lu J, Wang X, Wang W, Muniyappa H, Deshmukh A, Hu C, Das K, Mehta JL. Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation. Kidney Int. [Epub ahead of print].
48. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5: 39-44, 1990.
49. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E. Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int 33: 804-811, 1988.
50. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-1009, 2004.
51. Mento PF, Maita ME, Murphy WR, Holt WF, Wilkes BM. Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. J Cardiovasc Pharmacol 21: 791-796, 1993.
52. Michea L, Villagran A, Urzua A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 52: 295-300, 2008.
53. Moreno H Jr, Metze K, Bento AC, Antunes E, Zatz R, de Nucci G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol 91: 248-255, 1996.
54. Numabe A, Nishikimi T, Komatsu K, Frohlich ED. Intrarenal hemodynamics in low-and high-output cardiac failure in rats. Am J Med Sci 308: 331-337, 1994.
55. Ogino A, Takemura G, Kawasaki M, Tsujimoto A, Kanamori H, Li L, Goto K, Maruyama R, Kawamura I, Takeyama T, Kawaguchi T, Watanabe T, Moriguchi Y, Saito H, Fujiwara T, Fujiwara H, Minatoguchi S. Erythropoietin receptor signaling mitigates renal dysfunctionassociated heart failure by mechanisms unrelated to relief of anemia. J Am Coll Cardiol 56: 1949-1958, 2010.
56. Rabkin R, Awwad I, Chen Y, Ashley EA, Sun D, Sood S, Clusin W, Heidenreich P, Piecha G, Gross ML. Low-dose growth hormone is cardioprotective in uremia. J Am Soc Nephrol 19: 1774-1783, 2008.
57. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nagai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 125: 1402-1413, 2012.
58. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 92: 2934-2940, 1993.
59. Rambausek M, Ritz E, Mall G, Mehls O, Katus H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 28: 775-782, 1985.
60. Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, Losano G. Nitric oxide and cardiac function. Life Sci 81: 779-793, 2007.
61. Reddy V, Bhandari S, Seymour AM. Myocardial function, energy provision, and carnitine deficiency in experimental uremia. J Am Soc Nephrol 18: 84-92, 2007.
62. Ronco C. Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic definition. Int J Artif Organs 31: 1-2, 2008.
63. Santos-Araujo C, Roncon-Albuquerque R Jr, Moreira-Rodrigues M, Henriques-Coelho T, Quelhas-Santos J, Faria B, Sampaio-Maia B, Leite-Moreira AF, Pestana M. Local modulation of the natriuretic peptide system in the rat remnant kidney. Nephrol Dial Transplant 24: 1774-1782, 2009.
64. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75: 800-808, 2009.
65. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50: 1321-1326, 1996.
66. Szymanski MK, Buikema JH, van Veldhuisen DJ, Koster J, van der Velden J, Hamdani N, Hillege JL, Schoemaker RG. Increased cardiovascular risk in rats with primary renal dysfunction; mediating role for vascular endothelial function. Basic Res Cardiol 107: 242, 2012.
67. Takahashi H, Takeishi Y, Arimoto T, Shishido T, Konta T, Koyama Y, Niizeki T, Kubota I. Pitavastatin inhibits cardiac hypertrophy in a rat model of progressive renal injury. J Cardiovasc Pharmacol 46: 487-493, 2005.
68. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, El-Okdi N, Elkareh J, Gupta S, Gohara S, Fedorova OV, Cooper CJ, Xie Z, Malhotra D, Bagrov AY, Shapiro JI. Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension 54: 1313-1320, 2009.
69. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7: 667-675, 1996.
70. Tornig J, Gross ML, Simonaviciene A, Mall G, Ritz E, Amann K. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J Am Soc Nephrol 10: 77-83, 1999.
71. van Dokkum RP, Eijkelkamp WB, Kluppel AC, Henning RH, van Goor H, Citgez M, Windt WA, van Veldhuisen DJ, de Graeff PA, de Zeeuw D. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 15: 3103-3110, 2004.
72. Verhagen AM, Hohbach J, Joles JA, Braam B, Boer P, Koomans HA, Grone H. Unchanged cardiac angiotensin II levels accompany losartansensitive cardiac injury due to nitric oxide synthase inhibition. Eur J Pharmacol 400: 239-247, 2000.
73. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, Versluis K, Lagerwerf F, van Rijn H, Koomans H, Rabelink T. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 19: 1168-1172, 1999.
74. Winaver J, Ovcharenko E, Rubinstein I, Gurbanov K, Pollesello P, Bishara B, Hoffman A, Abassi Z. Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 290: H2007-H2014, 2006.
75. Windt WA, Eijkelkamp WB, Henning RH, Kluppel AC, de Graeff PA, Hillege HL, Schafer S, de Zeeuw D, van Dokkum RP. Renal damage after myocardial infarction is prevented by renin-angiotensinaldosterone-system intervention. J Am Soc Nephrol 17: 3059-3066, 2006.
76. Windt WA, Henning RH, Kluppel AC, Xu Y, de Zeeuw D, van Dokkum RP. Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. Nephrol Dial Transplant 23: 3103-3110, 2008.
77. Wolf SC, Gaschler F, Brehm S, Klaussner M, Amann K, Risler T, Brehm BR. Endothelin-receptor antagonists in uremic cardiomyopathy. J Cardiovasc Pharmacol 36: S348-S350, 2000.
78. Yuen DA, Connelly KA, Advani A, Liao C, Kuliszewski MA, Trogadis J, Thai K, Advani SL, Zhang Y, Kelly DJ, Leong-Poi H, Keating A, Marsden PA, Stewart DJ, Gilbert RE. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One 5: e9543, 2010.